Current type 2 diabetes (T2D) management requires additional interventions to achieve proper cardiometabolic benefit.

Oral semaglutide is the first glucagon-like peptide-1 receptor agonist available on the market, potentially allowing for a significant cardiometabolic risk reduction in a broader population of patients with T2D due to its innovative oral formulation.

We designed an innovative clinical trial to explore the possible anti-atherosclerotic effects of oral semaglutide, and its effects associated with arterial structure and function parameters in patients with T2D in primary cardiovascular prevention.

This is the first study to investigate the direct and indirect anti-atherosclerotic mechanisms of oral semaglutide, thus solidating its position in the multifactorial T2D management strategy, with emphasis on cardiovascular disease prevention.